Organogenesis Launches $75M ATM Equity Program After Q2 Revenue Plunge and Guidance Cut

summarizeSummary

Organogenesis launched a $75M at-the-market equity program, a highly dilutive capital raise coming on the same day as a disastrous Q2 report with a 58% revenue drop and slashed guidance. The stock is near its 52-week low, making the ATM particularly painful for existing holders.

check_boxKey Events · Financing and Capital Events · ORGO

• $75M ATM Program Established

  Organogenesis entered an at-the-market sales agreement with BTIG and Citizens JMP Securities to sell up to $75 million of Class A common stock from time to time, with a 3.0% commission.

• Highly Dilutive at Current Prices

  At the current stock price of $1.97, selling $75M would require approximately 38 million shares, expanding the outstanding share count by roughly 30% and causing significant dilution to existing shareholders.

• Convertible Preferred Anti-Dilution Trigger

  Sales below the convertible preferred conversion price of $3.7917 would automatically reduce the conversion price, increasing the shares issuable upon conversion — at the assumed $2.37 price, convertible shares would rise from 39.0M to 42.1M.

• Survival Capital After Q2 Disaster

  The ATM was filed the same day as an 8-K reporting Q2 revenue of $42.8M (down 58% YoY), a net loss of $96.3M, and sharply reduced full-year guidance — the company needs cash to fund operations and the ReNu BLA process.

auto_awesomeAnalysis · ORGO · Life Sciences

Organogenesis established a $75 million at-the-market equity offering program with BTIG and Citizens JMP Securities, just hours after reporting a disastrous Q2 — revenue fell 58% to $42.8M, net loss widened to $96.3M, and full-year guidance was slashed. The ATM allows the company to sell shares into the market at prevailing prices, which at $1.97 are near the 52-week low and well below the $2.37 assumed in the prospectus. At current levels, the program would be highly dilutive: selling $75M worth of stock would require roughly 38 million shares, expanding the share count by about 30%. The convertible preferred stock's anti-dilution provision would also trigger, increasing the shares issuable upon conversion and adding further overhang. This is a survival move — the company needs cash to fund operations, facility build-out, and the ReNu BLA process, but the cost to existing shareholders is steep.